Aspen buys MSD factory for R10,6bn

Aspen Group‚ the ninth largest generic pharmaceutical company in the world and the biggest in Africa‚ has signed an agreement with MSD to buy its active pharmaceutical ingredient (API) manufacturing business in the Netherlands.

28 Jun 2013

Agreement has also been reached for the API business on an option to acquire a portfolio of 11 branded finished dose form molecules from MSD, covering a diverse range of therapeutic areas and including products that use APIs manufactured by the API Business.

Stephen Saad‚ Aspen's chief executive‚ said: "One of Aspen's primary strategic intents is to globalise its business‚ increase its representation across a number of additional territories and provide support to its growing global presence with a differentiated pipeline of products. This transaction provides a platform to contribute to the achievement of this strategic goal by enabling Aspen to access a niche range of APIs and finished dosage products."

The transaction‚ which is subject to conditions precedent‚ is valued at US$1bn.

MSD is known as Merck in the US and Canada.

Source: I-Net Bridge

For more than two decades, I-Net Bridge has been one of South Africa’s preferred electronic providers of innovative solutions, data of the highest calibre, reliable platforms and excellent supporting systems. Our products include workstations, web applications and data feeds packaged with in-depth news and powerful analytical tools empowering clients to make meaningful decisions.

We pride ourselves on our wide variety of in-house skills, encompassing multiple platforms and applications. These skills enable us to not only function as a first class facility, but also design, implement and support all our client needs at a level that confirms I-Net Bridge a leader in its field.

Go to: http://www.inet.co.za